Participants will be placed on either drug or placebo and get routine normal care for 6 months. At the start and end of the study, participants will undergo different clinical measurements to see if the drug makes the sleep apnea better. ...
钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)在治疗2型糖尿病中的有效性和安全性重点
Analysis from the Empa-Reg Outcome((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. Kidney Int. 2019;96(2):489–504. 14. Wanner C, Inzucchi SE, ...
Therefore, new classes of medications on the horizon are aimed at attacking DM in new ways and targeting the conditions that coexist with DM, such as obesity and hypertension, in order to reduce the risk for end organ damage. Our understanding of the pathophysiology of diabetes has progressed ...
medications for T2DM, they do not appear to reduce the risk of cardiovascular (CV) outcomes and in the context of HF—some of these agents may even be harmful. A meta-analysis involving 95,000 individuals showed a 42% increased risk of incident HF with the use of thiazolidinediones in ...
lowering medications (combined GLP-1 RAs, DPP-4 inhibitors, or gliclazide;P = 0.049) [111]. Mechanisms of renal benefits with SGLT2 inhibitors The inhibition of SGLT2 leads to tubuloglomerular feedback via enhanced natriuresis and delivery of sodium to the macula densa, thereby decreasing ...
Nevertheless, some undesirable adverse effects caused by the administration of these medications, including hypoglycemia, gastrointestinal symptoms, weight gain, and hepato-renal toxicity, have increased demand for the discovery of safer antidiabetic agents with novel therapeutic mechanisms [3]. After the ...
Of the 2657 ligands tested, only 373 passed the ADMET filter. The numbers of candidate ligands that passed each parameter are presented inTable 1, and the list of the compounds that scored favorably in the ADMET profiling is provided in theSupplementary Materials (Table S1). ...